Stablecoin Development Corp. SDEV
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
What this company does
Written from the business description in NovaBay Pharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 19 March 2026. Every sentence was checked against that document before publication.
Growth
Revenue compounded at +8.2% a year over the five years to FY2024.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Return on equity has no reading this year — return on capital employed, just below, still does: -199%.
The 17-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | ◌ | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 |
| EBITDA $B | ◌ | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.6 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 |
| Free cash flow $B | ◌ | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 |
| EPS, diluted $ | ◌ | ◌ | ◌ | ◌ | −150.00 | −310.00 | −480.00 | −0.46 | −0.48 | −1.40 | −6.82 | −7.65 | −10.51 | −0.24 | −0.20 | −0.18 | 23115.00 |
| Dividend / sh $ | 4.00 | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % | −1 | −0 | — | — | — | — | −0 | — | — | — | — | — | — | — | — | — | — |
| ROE % | — | — | −139.0 | −102.4 | −51.8 | −166.1 | −325.9 | −173.4 | −152.7 | — | — | −293.2 | −142.2 | −60.1 | −51.3 | −36.1 | 20.2 |
| Shares out B | 0.03 | 0.00 | 0.01 | 0.00 | 0.05 | 0.04 | 0.03 | 0.02 | 0.02 | 0.02 | 0.00 | 0.05 | 0.04 | 0.04 | 0.03 | 0.02 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 15 of the 17 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. Six checks were skipped: the balance sheet is not tagged before 2010. Five checks were skipped: cost of revenue is not tagged before 2012. Two checks were skipped: EPS is not tagged before 2009.